Loading…
Loading…
REDWOOD CITY, CA / ACCESSWIRE / November 25, 2024 / Juva Life Inc. (CSE:JUVA)(OTC PINK:JUVAF)(FRANKFURT:4VV) ("Juva" or the "Company"), a life science company with both pharmaceutical research and development and consumer-facing operations in cannabis production and distribution, announces that, as of November 7, 2024, the Superior Court of California, County of San Joaquin, appointed Kevin Singer of Receivership Specialists as the court-appointed receiver to oversee the Company's assets. This follows the Company's prior disclosure on November 5, 2024, that it anticipated this outcome as part of ongoing efforts to address its financial challenges.
REDWOOD CITY, CA / ACCESSWIRE / November 5, 2024 / Juva Life Inc. (CSE:JUVA)(OTC EXPERT MARKET:JUVAF)(FRANKFURT:4VV) ("Juva" or the "Company"), a life science company with both pharmaceutical research and development and consumer-facing operations in cannabis production and distribution, has been facing a series of challenges that has hindered its ability to both operate as well as meet its financial obligations. This serves as an update to Juva's shareholders regarding recent developments within the Company.
REDWOOD CITY, CA / ACCESSWIRE / April 16, 2024 / Juva Life Inc. (CSE:JUVA)(OTCQB:JUVAF)(FRANKFURT:4VV) ("Juva Life" or the "Company"), Juva Life Inc, a life science company with both pharmaceutical research and development and consumer-facing operations in cannabis production and distribution, is thrilled to announce the upcoming launch of Rosin Absolute, a new cannabis vape category developed by its flagship brand, Frosted Flowers. Following the initial announcement on October 3, 2023, Frosted Flowers has been diligently working on bringing Rosin Absolute to the California marketplace.
REDWOOD CITY, CA / ACCESSWIRE / December 13, 2023 / Juva Life Inc. (CSE:JUVA)(OTCQB:JUVAF)(FRANKFURT:4VV) ("Juva Life" or the "Company"), Juva Life, Inc, a life science company with both pharmaceutical research and development and consumer-facing operations in cannabis production and distribution, is delighted to announce its financial results for the third quarter ending September 30, 2023. Key Highlights: Revenue Growth: Juva Life reported a substantial increase in sales, with Q3 2023 sales reaching $3.17 million, compared to $1.25 million for the same period in 2022.
Juva Life Inc. (OTCQB:JUVAF) Q2 2022 Earnings Conference Call September 6, 2022 4:30 PM ET Company Participants Doug Chloupek - CEO Mat Lee - CFO Sanjeev Gangwar - VP, Chemistry Conference Call Participants Operator Greetings and welcome to the Juva Life Second Quarter 2022 conference call. At this time all participants are in listen-only, and this conference is being recorded.
VANCOUVER, British Columbia, Oct. 14, 2021 (GLOBE NEWSWIRE) -- Juva Life Inc. (CSE: JUVA) (OTCQB: JUVAF) (FRANKFURT: 4VV) (“Juva Life,” “Juva” or the “Company”), a California based life sciences company focused on the research, development, and commercialization of Cannabis products today announced the advancement of the JUVA-19 class of compounds into formal development.
--Company identifies Non-Cannabinoid Anti-Inflammatory Compounds Suitable for Drug and Consumer Product Development --Company identifies Non-Cannabinoid Anti-Inflammatory Compounds Suitable for Drug and Consumer Product Development
--Website now open for Q&A submissions --Website now open for Q&A submissions
No recent filings indexed.